Literature DB >> 10491216

Intermittent administration of human parathyroid Hormone(1-34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice.

A Sakai1, T Sakata, S Ikeda, S Uchida, R Okazaki, T Norimura, M Hori, T Nakamura.   

Abstract

ddY mice, 6 weeks of age, were neurectomized (Nx) in the right hindlimbs and sham-operated (Sham) in the left limbs for evaluation of the effects of intermittent injections of human parathyroid hormone (hPTH) on trabecular bone turnover and bone marrow cell development in unloaded and loaded limbs. Mice were given subcutaneous injections of hPTH(1-34) five times a week at a dose of 0 (vehicle), 4 (low dose), or 40 (high dose) microg/kg of body weight for 2, 4, or 6 weeks. Histomorphometric analyses of the trabecular bone of the proximal tibiae revealed that high-dose hPTH injections preserved the trabecular bone volume of the Nx limbs, which was reduced after neurectomy, at the same level as that of the contralateral Sham limbs. The mineral apposition rate in the Nx limbs was elevated to values above even that of the Sham limbs by high-dose hPTH injections. The bone formation rate reduced by neurectomy was maintained at the Sham level by low- and high-dose hPTH injections. The neurectomy-induced increase in osteoclast number was suppressed by high-dose hPTH injections. In the bone marrow cells, the numbers of nonadherent and adherent cells per tibia obtained from the Nx and Sham limbs did not change. The hPTH injections decreased the numbers of nonadherent cells and increased those of adherent cells in both the Nx and the Sham limbs, but the effects were less marked in the Nx than in the Sham limbs even at high-dose injections. The formation of osteogenic nodules in the marrow cultures obtained from the Nx limbs was decreased after surgery and was maintained at the level of the Sham limbs by high-dose hPTH injections. The number of osteoclast-like multinucleated cells was reduced in the Sham limbs by high-dose hPTH injections. The value was increased at 2 weeks after neurectomy, but it was maintained at the Sham level by high-dose hPTH injections through the experimental period. The numbers of colony forming units-fibroblastic, which were reduced by neurectomy, and those of colony forming units for granulocytes and macrophages were not altered by hPTH injections. These results demonstrate that intermittent high-dose hPTH administration in the Nx limbs as well as in the contralateral Sham limbs has similar anabolic effects, stimulating osteoblast cell lineage and suppressing osteoclast cell lineage. The anabolic effects at 4 microg were reduced, but the effects at 40 microg seemed to be less affected by unloading due to sciatic neurectomy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491216     DOI: 10.1359/jbmr.1999.14.10.1691

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  14 in total

1.  Mesenchymal progenitors residing close to the bone surface are functionally distinct from those in the central bone marrow.

Authors:  Valerie A Siclari; Ji Zhu; Kentaro Akiyama; Fei Liu; Xianrong Zhang; Abhishek Chandra; Hyun-Duck Nah; Songtao Shi; Ling Qin
Journal:  Bone       Date:  2012-12-27       Impact factor: 4.398

2.  Constitutive protein kinase A activity in osteocytes and late osteoblasts produces an anabolic effect on bone.

Authors:  Richard S Kao; Marcia J Abbott; Alyssa Louie; Dylan O'Carroll; Weidar Lu; Robert Nissenson
Journal:  Bone       Date:  2013-04-10       Impact factor: 4.398

3.  Association of unipedal standing time and bone mineral density in community-dwelling Japanese women.

Authors:  A Sakai; N Toba; M Takeda; M Suzuki; Y Abe; K Aoyagi; T Nakamura
Journal:  Osteoporos Int       Date:  2008-09-02       Impact factor: 4.507

4.  Hypercalcemia due to Milk-Alkali Syndrome and Fracture-Induced Immobilization in an Adolescent Boy with Hypoparathyroidism.

Authors:  Rohan K Henry; Rachel I Gafni
Journal:  Horm Res Paediatr       Date:  2016-05-18       Impact factor: 2.852

Review 5.  Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.

Authors:  Robert L Jilka
Journal:  Bone       Date:  2007-04-06       Impact factor: 4.398

6.  Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.

Authors:  Akimitsu Miyauchi; Toshio Matsumoto; Hirofumi Shigeta; Mika Tsujimoto; Daniel Thiebaud; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2008-11-01       Impact factor: 2.626

7.  Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells.

Authors:  Tomonori Taketa; Akinori Sakai; Shinya Tanaka; Kenichiro Nakai; Kunitaka Menuki; Hirotoshi Yamane; Kazuhiro Tanaka; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2008-02-27       Impact factor: 2.626

8.  Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis.

Authors:  Takanori Yamamoto; Mika Tsujimoto; Etsuro Hamaya; Hideaki Sowa
Journal:  J Bone Miner Metab       Date:  2012-11-08       Impact factor: 2.626

9.  Unipedal standing exercise and hip bone mineral density in postmenopausal women: a randomized controlled trial.

Authors:  Akinori Sakai; Toshihisa Oshige; Yukichi Zenke; Yoshiaki Yamanaka; Hitoshi Nagaishi; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2009-06-12       Impact factor: 2.626

10.  Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes.

Authors:  Ji Zhu; Valerie A Siclari; Fei Liu; Jordan M Spatz; Abhishek Chandra; Paola Divieti Pajevic; Ling Qin
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.